M. Lei

发表

Establishing a High-content Analysis Method for Tubulin Polymerization to Evaluate Both the Stabilizing and Destabilizing Activities of Compounds

L. Schweizer, C. Sum, Litao Zhang, 2014, Current chemical genomics and translational medicine.

Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression

P. Ross-Macdonald, S. Kirov, L. Schweizer, 2015, Molecular Cancer Therapeutics.

The discovery of macrocyclic XIAP antagonists from a DNA-programmed chemistry library, and their optimization to give lead compounds with in vivo antitumor activity.

Shana L. Posy, J. Fargnoli, R. Talbott, 2015, Journal of medicinal chemistry.

Building homogeneous time-resolved fluorescence resonance energy transfer assays for characterization of bivalent inhibitors of an inhibitor of apoptosis protein target.

Shana L. Posy, W. Metzler, R. Talbott, 2016, Analytical biochemistry.

Neuropilin-1 is a valuable biomarker for predicting response of advanced non-small cell lung cancer patients to hypofractionated radiotherapy and PD-1 blockade.

Sheng Lin, M. Lei, Zhi Hu, 2022, International immunopharmacology.

Discovery of tetrahydroisoquinoline-based bivalent heterodimeric IAP antagonists.

Shana L. Posy, R. Talbott, S. Emanuel, 2014, Bioorganic & medicinal chemistry letters.

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

J. Ajani, T. Zander, A. Lièvre, 2021, The New England journal of medicine.

A Small Molecule Inhibitor Selectively Induces Apoptosis in Cells Transformed by High Risk Human Papilloma Viruses

B. Beno, L. Schweizer, M. Lei, 2016, PloS one.

LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

J. Ajani, Y. Janjigian, L. Wyrwicz, 2020 .

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

J. Ajani, Y. Doki, L. Wyrwicz, 2022, The New England journal of medicine.

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.

M. Sawyer, E. Van Cutsem, H. Lenz, 2019, Journal of Clinical Oncology.

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.

J. Ajani, Y. Doki, Jianming Xu, 2021 .

Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

M. Sawyer, E. Van Cutsem, B. Neyns, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Dimeric Macrocyclic Antagonists of Inhibitor of Apoptosis Proteins for the Treatment of Cancer.

Shana L. Posy, J. Fargnoli, R. Talbott, 2015, ACS medicinal chemistry letters.

Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.

J. Fargnoli, R. Talbott, S. Emanuel, 2015, Journal of medicinal chemistry.

HTRF assays for characterization of bivalent inhibitors of an Inhibitor of Apoptosis Protein target

Shana L. Posy, W. Metzler, R. Talbott, 2015 .

Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC)

P. Sharma, Han Chang, N. Siemers, 2019, Clinical Research (Excluding Clinical Trials).

Exploration of structure–activity relationships at the two C-terminal residues of potent 11mer Glucagon-Like Peptide-1 receptor agonist peptides via parallel synthesis

Christopher B. Cooper, B. Koplowitz, C. Mapelli, 2010, Peptides.

Identification of potent 11mer Glucagon-Like Peptide-1 Receptor agonist peptides with novel C-terminal amino acids: Homohomophenylalanine analogs

Christopher B. Cooper, C. Mapelli, V. Lee, 2010, Peptides.

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

J. Ajani, T. Zander, M. Karamouzis, 2021, The Lancet.

Establishing a High-Throughput and Automated Cancer Cell Proliferation Panel for Oncology Lead Optimization

L. Schweizer, Larnie Myer, Litao Zhang, 2013, Journal of biomolecular screening.

Tumor‐immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas

B. Ylstra, G. Hooijer, S. Meijer, 2021, The Journal of pathology.

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

T. Owonikoko, Han Chang, Yoon-Koo Kang, 2022, Journal for ImmunoTherapy of Cancer.

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

J. Ajani, T. Zander, M. Karamouzis, 2022, Nature.

LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study

J. Ajani, Y. Janjigian, L. Wyrwicz, 2021, Annals of Oncology.

LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study

J. Ajani, T. Zander, A. Lièvre, 2020 .

Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer

P. Sharma, F. D. De Braud, Han Chang, 2021, Clinical Cancer Research.

Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.

J. Ajani, M. Karamouzis, Y. Janjigian, 2023, Journal of Clinical Oncology.

Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe

M. Favata, J. Trzăskos, A. Tebben, 2007, Proceedings of the National Academy of Sciences.

A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW.

H. Lenz, S. Tejpar, J. Novotny, 2020, Journal of Clinical Oncology.

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.

J. Ajani, Y. Janjigian, L. Wyrwicz, 2021 .

SDRS—an algorithm for analyzing large-scale dose–response data

Ming Lei, Robert E. Bruccoleri, Rui-Ru Ji, 2011, Bioinform..

1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577

J. Ajani, T. Zander, A. Lièvre, 2021, Annals of Oncology.

Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.

J. Ajani, T. Zander, A. Lièvre, 2021 .

Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

E. Van Cutsem, M. Overman, S. Lonardi, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of potent 11mer Glucagon-Like Peptide-1 Receptor agonist peptides with novel C-terminal amino acids: Homohomophenylalanine analogs

Christopher B. Cooper, C. Mapelli, V. Lee, 2010, Peptides.

Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.

J. Ajani, Y. Doki, L. Wyrwicz, 2022, Journal of Clinical Oncology.

First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

Y. Ba, Wen-Wei Hu, Wei Li, 2022, International journal of cancer.

Abstract CT037: Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses

J. Ajani, T. Zander, M. Karamouzis, 2023, Cancer Research.

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.

G. Tortora, R. García-Carbonero, T. Yoshino, 2024, Journal of Clinical Oncology.